Pioneering Transformational and Disruptive Technologies

Developing First-in-Class Novel Pan-Cancer Biologics

NomoCan’s  
Breakthrough Platform

First-in-Class
Conformational Biologics

At NomoCan, we are building a revolutionary oncology platform that integrates high-specificity diagnostics with first-in-class therapeutics, precisely engineered to target core cancer-driving pathways across multiple tumor types.

Our approach is

Highly Selective and Specific Tumor Targets
Targets expressed across various solid and liquid tumors, absent in normal tissue

Robust First-in-Class Therapeutics
Pioneering therapeutics against specific proprietary conformational epitopes

Pan-Cancer by Design
Enabling both detection & precision-targeted therapy for some the most aggressive cancers

World Leading Scientific and Clinical Experts
Backed by 14+ years of domain expertise, that revealed a previously overlooked opportunity.

Conformational Biologics

NomoCan’s novel biologics bind exclusively to specific conformational epitopes on proteins in cancer cells, unlocking superior efficacy with a significantly improved safety profile.

Non-Invasive Liquid Biopsy Detection

The tumor-restricted nature of our First-in-Class biologics provides a strong foundation for the development of highly selective diagnostic and prognostic assays leveraging non-invasive liquid biopsy, enabling early detection, patient stratification, and precision-guided treatment strategies.

First-in-Class
Therapeutics

Building on this breakthrough, NomoCan has developed First-in-Class targeted biologics for the treatment of some of the most aggressive cancers with unmet medical need.

Unparalleled Precision Oncology Approach

LIQUID BIOPSY + NOMOCAN BIOLOGICS

First-in-Class
Biologics

Selective

Specific

Highly Efficacious

Safe

Powering Early Detection and Precision Guided Oncology

Liquid Biopsy Diagnostics

Trans_AdobeStock_518810651_Preview copy.png

Revolutionizing cancer detection and treatment through integrated liquid diagnostics and targeted therapeutics.

Precision-Guided Treatment

Patient Stratification

Fully integrated with NomoCan's therapeutics. Delivering personalized, targeted oncology care.

Identifies patients most likely to respond
to NomoCan's therapeutics and optimizes treatment selection and improves clinical outcomes.

Pipeline

NomoCan's oncology therapeutics are able to selectively identify and diagnose cancer in human tumors. With a high affinity for their targets, these biologics demonstrate potent anti-tumor activity against freshly excised patient tumors as well as in rodent models, providing a groundbreaking opportunity to initiate first-in-human clinical trials. Moreover, these biologics have demonstrated stand-alone or companion diagnostic utility. In non-oncology settings, NomoCan's assets demonstrate robust therapeutic activity in critical ophthalmology indications.